ETFs Holding ACRX »    ACRX Historical Stock Prices »
ACRX News Video: Tue, Aug 1, 2017, 1:44 PM — Tuesday Sector Laggards: Trucking, Drugs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Co.'s primary product candidate, DSUVIA (known as ARX-04 outside of the U.S.), consists of a single tablet delivered via a disposable, pre-filled, single-dose applicator. Co. is developing DSUVIA for the treatment of moderate-to-severe acute pain to be administered by a healthcare personnel to a patient in medically supervised settings. In addition, Co.'s follow-on product candidate, ZALVISO®, is designed for the management of moderate-to-severe acute pain in hospitalized adult patients. Self directed investors in AcelRx Pharmaceuticals Inc will be interested in keeping up with all AcelRx Pharmaceuticals Inc news they can find, both ACRX news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACRX. At RediNews, we simplify this task by presenting both ACRX news releases originating from AcelRx Pharmaceuticals Inc itself, and ACRX news from a variety of media outlets. Visitors can browse this news online and through our ACRX RSS news feed.


ACRX News — Articles, Videos, & Press Releases

Omeros Inks Agreement With FDA for OMS721 Phase III Trial
Thursday, January 4, 2018, 8:42 AM — Zacks
Merck's Keytruda Gets Approved for Bladder Cancer in Japan
Wednesday, January 3, 2018, 2:42 PM — Zacks
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
Wednesday, January 3, 2018, 9:03 AM — Zacks
5 Reasons to Pick Emergent as an Investment-Worthy Stock
Wednesday, January 3, 2018, 2:23 AM — Zacks
Actinium Posts Positive DMC View on Lomab-B Phase III Trial
Thursday, December 28, 2017, 8:45 AM — Zacks
AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
Friday, October 13, 2017, 9:05 AM — Zacks
Insider Bets Paying Off At ACRX As New 52-Week High Reached
Monday, October 2, 2017, 1:11 PM — Market News Video
3 Biotech and Pharma Stocks with Key FDA Catalysts this October
Monday, October 2, 2017, 7:11 AM — Zacks
First Week of ACRX November 17th Options Trading
Wednesday, September 20, 2017, 11:07 AM — Stock Options Channel
Interesting ACRX Call Options For March 2018
Monday, July 24, 2017, 11:38 AM — Stock Options Channel
Sum Up The Pieces: VTWG Could Be Worth $136
Tuesday, July 11, 2017, 8:37 AM — ETF Channel
Noteworthy Tuesday Option Activity: BBBY, ACRX, GS
Tuesday, June 20, 2017, 3:24 PM — Stock Options Channel
Sum Up The Parts: IWO Could Be Worth $187
Tuesday, June 6, 2017, 9:24 AM — ETF Channel
Notable Monday Option Activity: CUDA, ACRX, ABY
Monday, April 17, 2017, 3:32 PM — Stock Options Channel
How The Parts Add Up: PXSG Headed For $32
Friday, March 31, 2017, 8:51 AM — ETF Channel
Implied PXSG Analyst Target Price: $31
Monday, February 27, 2017, 9:00 AM — ETF Channel
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%
Monday, February 6, 2017, 7:00 AM — Zacks
Analysts Expect 19% Gains Ahead For PXSG
Tuesday, January 24, 2017, 9:18 AM — ETF Channel
Commit To Buy AcelRx Pharmaceuticals At $2.50, Earn 47.8% Annualized Using Options
Friday, December 30, 2016, 11:33 AM — Stock Options Channel
Implied PXSG Analyst Target Price: $30
Wednesday, December 21, 2016, 9:34 AM — ETF Channel
The Implied Analyst 12-Month Target For PXSG
Tuesday, November 15, 2016, 9:23 AM — ETF Channel
ACRX: Insiders vs. Shorts
Thursday, October 13, 2016, 2:23 PM — Market News Video
Commit To Purchase AcelRx Pharmaceuticals At $2.50, Earn 21.7% Annualized Using Options
Friday, September 30, 2016, 11:43 AM — Stock Options Channel
Company News for September 16, 2016
Friday, September 16, 2016, 8:10 AM — Zacks
Analysts Predict 16% Upside For The Holdings of PXSG
Friday, September 9, 2016, 7:56 AM — ETF Channel
How The Pieces Add Up: PXSG Headed For $30
Monday, August 8, 2016, 7:22 AM — ETF Channel
Commit To Purchase AcelRx Pharmaceuticals At $2.50, Earn 43.2% Annualized Using Options
Thursday, June 30, 2016, 11:54 AM — Stock Options Channel
First Week of ACRX September 16th Options Trading
Wednesday, January 27, 2016, 10:40 AM — Stock Options Channel
AcelRx Updates on Zalviso for Pain Management Treatment
Thursday, October 8, 2015, 3:00 PM — Zacks
New Strong Buy Stocks for October 1st
Thursday, October 1, 2015, 7:30 AM — Zacks
AcelRx Pharmaceuticals (ACRX) Enters Oversold Territory
Thursday, October 1, 2015, 6:22 AM — Zacks
Why Valeant's (VRX) Shares Plummeted in Monday Trading
Tuesday, September 29, 2015, 2:41 PM — Zacks
New Strong Buy Stocks for September 29th
Tuesday, September 29, 2015, 7:30 AM — Zacks
PDL BioPharma Concludes Financing Agreement with Avinger
Thursday, September 24, 2015, 1:25 PM — Zacks
Valeant's Glaucoma Drug Accepted for Review by the FDA
Wednesday, September 23, 2015, 2:05 PM — Zacks
AcelRx's Pain Treatment Drug Zalviso Approved in Europe
Wednesday, September 23, 2015, 2:00 PM — Zacks
PDL BioPharma to Get Royalties on AcelRx's Zalviso Sales
Tuesday, September 22, 2015, 3:58 PM — Zacks
Why AceIRx (ACRX) Could Be a Potential Winner
Friday, August 21, 2015, 6:32 AM — Zacks
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 12.5%
Tuesday, August 11, 2015, 6:51 AM — Zacks
New Strong Buy Stocks for August 4th - Tale of the Tape
Tuesday, August 4, 2015, 7:30 AM — Zacks
Cempra (CEMP) in Focus: Stock Rises 7.2% - Tale of the Tape
Tuesday, January 6, 2015, 7:44 AM — Zacks
Zacks Rank #1 Additions for Monday - Tale of the Tape
Monday, January 5, 2015, 8:30 AM — Zacks
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Wednesday, December 31, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Monday - Tale of the Tape
Monday, December 29, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Thursday, December 18, 2014, 8:30 AM — Zacks
Xencor, Inc. (XNCR) in Focus: Stock Soars 29.6% - Tale of the Tape
Thursday, December 18, 2014, 8:21 AM — Zacks
Zacks Rank #1 Additions for Monday - Tale of the Tape
Monday, December 15, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Thursday, November 20, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Tuesday, November 11, 2014, 8:30 AM — Zacks
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Tuesday, November 11, 2014, 7:30 AM — Zacks
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Monday, February 10, 2014, 9:35 AM — Zacks
Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Tuesday, January 28, 2014, 7:47 AM — Zacks
NDA for AcelRx's Zalviso Accepted - Analyst Blog
Thursday, December 5, 2013, 6:04 PM — Zacks
ACRX is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

SSH News
Q News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACRX News | | Copyright © 2013 - 2018, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.